51 results about "Arenobufagin" patented technology

The invention discloses a secretio bufonis nano liposome which comprises the following constituents (by weight portions): 0.01-1 part of toad venoms extract, 0.1-20 of phospholipids, 0.05-10 parts of cholesterin, and 0.1-10 parts of emulsifying agent. The invention also discloses the process for preparation through film membrane dispersion method. The secretio bufonis nano liposome has a grain size between 10-100nm and the advantages of high medicinal encapsulation efficiency, low medicinal percolation ratio and oxidation index, and better constancy.

The invention provides a Chinese drug for curing the oesophagus cancer, which comprises a Chinese drug A and a Chinese drug B. The Chinese drug A adopts a hard honeyed pill which is prepared by bornel, cow bezoar, arenobufagin, agalloch, musk, saliter, sal ammoniac, pearl, chlorite schist, asafetida and notoginseng according to a certain proportion by weight, and the Chinese drug B adopts soft honeyed pill which is prepared by Chinese angelica root, root of herbaceous peony, safflower, rhizoma chiuanxiong, burred tuber, zedoary, pinellia, aucklandia root, amomum fruit, corydalis tuber, bitter orange, cuttlebone, barbed stullcap, oldenlandia, arrowhead, aloe, ginseng, atractylodes macrocephala, dried rehmannia root and licorice root according to a certain proportion by weight, and the Chinese drug A and B are separately packed and used together. The Chinese drug for curing the oesophagus cancer has good effects on curing middle-advanced oesophagus cancer, curing hiccought, relieving obstruction and restraining and killing cancer cells.

The invention discloses secretio bufonis solid liposome nano particles which comprise the following constituents (by weight portions): 0.01-1 part of toad venoms extract, grease material 0.2-20 parts, liposoluble emulsifying agent 0.2-15 parts, and water-soluble emulsifying agent 0.2-10 parts. The grease material is selected from stearinic acid, glycol tristearate and mountain-elm glyceride. The invention also discloses the process for preparation through fusion method and high pressure homogeneity. The secretio bufonis nano liposome has a grain size between 10-100nm and the advantages of high medicinal encapsulation efficiency, low medicinal percolation ratio and oxidation index, and better constancy.

A dripping pill of toad venom for treating pyogenic infection or as the auxiliary anticancer medicine is prepared from toad venom and medicinal carrier.

The invention relates to the technical field of traditional Chinese medicines and in particular discloses venenum bufonis extract with anti-infection action and a preparation method thereof. The venenum bufonis extract contains a phrynin effective component which contains the following components in parts by weight: 30-60 parts of arenobufagin, 35-60 parts of cinobufagin, 10-25 parts of telocinobufagin, 20-45 parts of bufotaline, 20-50 parts of cinobufotalin, 25-45 parts of bufalin, 15-40 parts of resibufogenin and 5-15 parts of hellebrigenin. The venenum bufonis extract provided by the invention is remarkable in anti-infection effect. In addition, the types and content of effective components of the extract are clear, the cytotoxicity is small, and quality control and medicinal safety of the extract are facilitated.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a local anesthetic for an operative incision. The local anesthetic is prepared from the following traditional Chinese medicine materials in parts by weight: 5-10 parts of girald daphne bark, 5-15 parts of flos daturae, 5-10 parts of passion flower, 5-10 parts of hyoscyamus niger, 3-5 parts of decumbent corydalis tuber, 3-8 parts of shinyleaf pricklyash root, 3-5 parts of cynanchum paniculatum, 3-5 parts of centipede, 1-3 parts of caulis spatholobi, 1-3 parts of unprocessed semen strychni, 3-5 parts of asarum, 3-5 parts of arenobufagin, 3-5 parts of pepper, 3-5 parts of angelica sinensis, 3-5 parts of arisaema erubescens and 1-3 parts of flos carthami. The local anesthetic is prepared into a surgical dressing by virtue of a preparation method and used in a local anaesthesia fiber so as to be bound at an operative incision. Through the efficacies of anesthesia, analgesia, spasmolysis and convulsion check and the efficacies of drawing out poison, promoting granulation, removing blood stasis and relieving pain, the effects of rapid permeation, sedation and analgesia before an operation are achieved; the dosage of the injected local anesthetic is reduced in an assisting manner; and the local anesthetic has multiple effects of lasting anesthesia and analgesia after the operation, promoting incision healing and the like.

A Chinese materia medica preparation for treating cerebrovascular diseases is characterized by being made from the following traditional Chinese medicine raw materials by weight: 10-15 parts of prepared pinellia , 10-15 parts of arisaema with bile, 3-5 parts of bezoar, 3-5 parts of musk, 10-15 parts of borneol, 10-15 parts of storax, 2-3 parts of arenobufagin, 20-25 parts of safflower, 20-25 parts of red sage root, 20-25 parts of red peony root, 20-25 parts of hemlock parsley, 10-15 parts of Chinese rhubarb, 10-15 parts of moutan bark, 10-15 parts of corydalis tuber, 10-15 parts of agilawood, 10-15 parts of nutgrass, 10-15 parts of snakegourd fruit, 10-15 parts of vermilion, 20-25 parts of gambir vine, 20-25 parts of ptunella spike, 5-10 parts of dragons blood, 5-10 parts of batryticated silkworm, 5-10 parts of cicada slough, 3-5 parts of scorpion, and notoginseng which accounts for 5-15% of the total weight. The total effective rate of the Chinese materia medica preparation for treating various cardiovascular and cerebrovascular diseases, sequelaes and complications thereof is 92.5%.

The invention discloses a use of a bufadienolide compound in preparing medicines for treating oral mucosal malignant tumors. Anti-cancer experiments of human tongue squamous cancer cells are carried out in vitro through a bufadienolide extract and monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, cinobufagin, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, and experimental results show that the bufadienolide compound has strong inhibition effect on tongue squamous cancer cells and compared with the bufadienolide extract and eight monomeric compounds, namely gamabufalin, arenobufagin, telocinobufagin, bufotaline, desacetylcinobufotalin, heloniogenin, resibufogenin, and cinobufotalin, cinobufagin has a stronger anti-tumor cell activity. The bufadienolide compound provided by the invention has clear components, controllable quality, strong anti-tumor activity and little adverse reaction and is expected to be developed into a novel anti oral mucosal malignant tumor medicine.

The invention discloses single-dosage package arenobufagin. The single-dosage package arenobufagin is characterized in that white slurry of ear-side glands and dermal gland of bufo bufo gargarigans or bufo melanostictus is taken to be screened to remove impurities and to be dried at low temperature, and smashing is conducted to obtain arenobufagin powder. Single-dosage package is conducted according to the adult single dosage of the total amount, being 0.08-10 mg, of cinobufagin and resibufogenin, and the package difference limit is smaller than or equal to +/-15% according to the net weight, being 1-100 mg, of arenobufagin in the single-dosage package. The small-package arenobufagin is suitable for traditional Chinese medicine decoctions, pills and powder and suitable for external application. By means of the low-temperature drying, particularly freezing drying technology, active components of arenobufagin are kept to the maximum extent; by strictly controlling the total amount of cinobufagin and resibufogenin in the single-dosage package, the use safety problem of arenobufagin is effectively solved, and the last barrier is broken for clinical application of arenobufagin.

The invention discloses a traditional Chinese drug named as 'qukedan' therapying the oesophagus cancer, formed mainly from Lapis Chloriti, Borax, Salmiac, Cormu satgae, Borneol, Blue vitriol, Agilawood, Arenobufagin, Pangolin, Bezoar, Musk and Sesame oil at a certain proportion by weight. The 'qukedan' has effects such as blood-cooling, detumescence, dissipating hard mass, dissolving membrane, rupturing membrane, getting through the tumour of gullet. The usage of the 'qukedan'is that: when the patients suffering from gullet tumour and carcer can not eat anything even water, the serious ones keep one pill in mouth for half an hour until the stickies in a mixed color of red, white and yellow with mucosity and sticky foam are spitted, therefore the tumour is dissolved and broken. When the paitients can eat liquid diet, the time for keeping one pill in mouth is changed to be three hours. After continual keeping one pill in mouth for three days, the paitient stops taking the 'qukedan'. The 'qukedan' is a hereditary skill handed down from five ancestors, making contributions for therapying the oesophagus cancer. The 'qukedan' can make the tumor membrane break and drop out. therefore the lumen is broadened and unobstructed. The 'qukedan' can also avoid the patients dying from thirst and starvation and reduce patients pain of operation and the expensive operation cost.

The invention discloses externally-applied medicine for treating herpes zoster. The externally-applied medicine is prepared from, by weight, 2-8 parts of pearls, 5-15 parts of calculus bovis, 5-15 parts of realgar, 2-8 parts of borneol, 5-15 parts of arenobufagin, 5-15 parts of musk, 5-15 parts of panax notoginseng, 5-15 parts of cinnabar and 25-35 parts of rice vinegar. According to the externally-applied medicine, raw materials are scientifically and reasonably matched and support one another, and through combination of the raw medical materials, the effects of clearing away heat and toxic materials and activating blood to promote menstruation and relieve pain are realized, treatment time is short, and the medicine becomes effective fast and is free of toxic and side effects. The medicine is especially suitable for treating herpes zoster.

The present invention relates to anti-gastric cancer drugs, in particular to the application of bufadienolactone compounds in anti-gastric cancer drugs. Diacyl arginine ester, cinobufagin-3-adipyl arginine ester, cinobufagin, deacetylated cinobufagin, cinobufagin-3-suberoyl arginine Esters, bufafolin-3-suberoyl arginine ester, 3-dehydrobufafolin and sea bufotoxin and their pharmaceutically acceptable salt-forming compounds. In vitro cell experiments show that the compound of the present invention can significantly inhibit the growth of gastric cancer cell spheres, and therefore can be used to prepare tumor drugs for treating gastric cancer.

The invention discloses an improved tablet medicament with hairy vein agrimony and arenobufagin. The medicament comprises the following raw material drugs as active components by weight part: 40 to 60 parts of nuxvomica poison nut seed powder, 0.5 to 1.5 parts of the arenobufagin, 100 to 200 parts of psoralea, 40 to 60 parts of pinellia tuber, 40 to 60 parts of turmeric, 20 to 40 parts of ginseng, 10 to 30 parts of hoantchy root, 10 to 30 parts of angelica, and 40 to 60 parts of the hairy vein agrimony. Simultaneously, the invention improves a process for preparing the original tablet with the hairy vein agrimony and the arenobufagin; compared with the prior tablet with the hairy vein agrimony and the arenobufagin, the process reduces dosage of the arenobufagin, proves that the improvement is successful with the anti-cancer effect unreduced through three-batch trial production and research of arenobufagin content measurement methodology and determination of content limit by using the three batches of samples.

The invention discloses anti-cancer and hemostatic Chinese patent drug which comprises the following components by weight: 150 to 200 parts of salsola-like inula flower and herb, 100 parts of white atractylodes rhizome, 100 parts of zedoary, 100 parts of Chinese angelica root, 100 parts of psoralea fruit, 100 parts of pinellia tuber, 100 parts of fritillary bulb, 100 parts of asarum sagittarioides, 60 parts of ginseng, 40 parts of American ginseng, 50 parts of astragalus root, 50 parts of white peony root, 30 parts of rhizome of Sichuan lovage, 50 parts of ass-hide glue, 50 parts of bark of chinese cassia tree, 40 parts of Mabuzi, 7 parts of Banmo, 3 parts of arenobufagin and 40 parts of borneol. The Chinese patent drug has the effects that the curative effect is quick, the Chinese patent drug can effectively restrain complications, is broad-spectrum and anti-cancer, safe, reliable, short in course of treatment, and overcomes the problem of the multidrug resistance of cancer cells, patients can not suffer a relapse after being healed, and the Chinese patent drug has the function of improving the medullary hematopoiesis.

The invention relates to medicine, in particular to a novel traditional Chinese medicine formula for tumor treatment containing scorpion venom macromolecules. The novel traditional Chinese medicine is composed of, by weight, 20-30 g of kudzu vine roots, 15-20 g of prunella vulgaris, 5-9 g of paris polyphylla, 30-40 g of oldenlandia diffusa, 5-9 g of mangnolia officinalis, 3-10 g of pericarpium citri reticulatae viride, 10-15 g of poria cocos, 30-70 g of monkshood, 3-10 g of ligusticum wallichii, 5-9 g of sappanwood, 6-12 g of zedoary, 3-5 g of leeches, 0.03-0.06 g of Chinese blister beetles, 6-12 g of seaweed, 5-15 g of earthworms, 3-5 g of scorpion, 3-5 g of centipedes, 0.015-0.03 g of arenobufagin, 30-60 g of astragalus membranaceus, 3-6 g of cordyceps sinensis, 9-15 g of flatstem milkvetch seeds, and 10-20 g of herba epimedii. By means of compatibility of different kinds of traditional Chinese medicine, equilibrium between yin and yang in the body can be achieved, body immunity can be improved, and tumors can be suppressed or eliminated.

The invention discloses traditional Chinese medicinal powder with effects of dredging collaterals, activating blood, dispersing blood stasis and relieving swelling and pain. The traditional Chinese medicinal powder is characterized by being prepared from the following traditional Chinese medicinal raw materials in parts by weight: 5 to 10 grams of schizophragma, 5 to 10 grams of herba sarcandrae, 5 to 10 grams of plantain herb, 4 to 8 grams of liquidambar formosana hance, 3 to 9 grams of giantleaf ardisia rhizome, 5 to 10 grams of little multibanded krait, 5 to 10 grams of long-noded pit viper, 5 to 10 grams of zaocys dhumnade, 3 to 8 grams of radix clematidis, 4 to 11 grams of arenobufagin, 3 to 9 grams of caulis trachelospermi, 1 to 6 grams of Ligusticum wallichii, 2 to 8 grams of drynaria rhizome, 2 to 7 grams of woodlouse, 3 to 10 grams of homalomena occulta, 2 to 10 grams of centipede, 2 to 10 grams of scorpion, 3 to 8 grams of decumbent bugle herb and 5 to 13 grams of gynura segetum. The medicament is very outstanding in effects of treating uncomfortable symptoms such as gall, numb and swelling in parts such as joints, cervical vertebra, lumbar vertebra, shoulders, hands and feet, has the characteristics of high curing rate, short treating period, difficulty in allergy and no side effect, is convenient for household self-recovery and is also suitable for clinical treatment of all levels of medical mechanisms.

The invention discloses external use medicinal liquor for traumatic injury. The external use medicinal liquor is prepared by soaking the following raw materials in parts by weight: 12-18g mastic, 12-18g myrrh, 8-12g radix aconiti agrestis, 10-15g amber, 12-18g red flowers, 8-12g liquorice, 8-12g cortex moutan, 8-12g eucommia ulmoides, 12-18g radices trichosanthis, 8-12g radix achyranthis bidentatae, 12g angelica sinensis, 12-18g rhizoma drynariae, 8-12g daemonorops draco, 8-12g cortex cinnamomi, 18-25g eupolyphoge sinensis, 8-12g pseudo-ginseng, 8-12g elecampane, 8-12g angelica, 3-8g arenobufagin, 8-12g garden balsam stem, 12-18g thymol crystals, 18-25ml azone and 1000g yellow rice wine or grain liquor. The invention discloses a preparation method for the medicinal liquor. The medicinal liquor disclosed by the invention can fast become effective, has a long-lasting effect, is high in cure rate and is wide in use scope for traumatic injury.

The invention discloses a narcotic analgesic for operative incisions. The narcotic analgesic is prepared from the following medicinal materials in parts by weight: 15-20 parts of radix ranunculi ternate, 4-8 parts of usnea, 4-6 parts of cortex mori radicis, 4-6 parts of climbing nightshade fruit, 1-3 parts of crocus sativus, 4-5 parts of flos daturae, 4-5 parts of chelidonium majus, 3-4 parts of ecucalytypus leaves, 0.2-0.3 part of arenobufagin, 2.5-3 parts of mimosa pudica, 2.5-3 parts of aconitum pendulum, 9-10 parts of sungpan monkshood root, 15-25 parts of centella asiatica, 0.8-1 part of acutangular anisodus root, 1-5 parts of angelica sinensis and 1-9 parts of pleione bulbocodioides. The narcotic analgesic has narcotic and analgesic composite effects, and has the effects of inhibiting proliferation of fibrous tissues and promoting skin growth.

The invention relates to the technical field of feeds for aquatic animals, and in particular relates to a complete compound feed for eel aquaculture. The feed is prepared from the following raw materials in parts by weight: 80-100 parts of rice bran, 30-40 parts of wheat gluten, 20-25 parts of soybean meal, 15-20 parts of pig blood, 10-12 parts of fistular onion stalks, 20-25 parts of silkworm chrysalis powder, 0.03-0.05 part of Roche multidimensional I, 0.01-0.015 part of arenobufagin, 0.2-0.5 part of cinnamomum camphora fruits, 1.5-1.7 parts of persimmon leaves, 1.5-2 parts of lithospermum, 0.3-0.4 part of gemma agrimoninae, 0.05-0.07 part of crinis carbonisatus, 0.8-1 part of folium callicarpae pedunculalae, 0.02-0.025 part of fructus cannabis, 2-4 parts of phyllanthus ruinaria, 0.5-0.7 part of vitamin E and 1-1.5 parts of sodium bicarbonate. The feed disclosed by the invention is rich in nutrition and high in utilization rate; the daily weight gain can be obviously increased, and infection with bacterial diseases, fungal diseases and parasitic diseases in the eel aquaculture process can be effectively prevented, so that the artificial eel aquaculture survival rate is increased, and obvious effects of promoting and improving eel growth, nonspecific immunity, activity of digestive enzyme and quality of eel bodies are achieved.

The invention discloses an external application medicine for treating herpes zoster. The medicine is characterized by comprising, by weight, 15 parts of bear gall powder, 20 parts of realgar, 5 partsof arenobufagin, 30 parts of rheum officinale, 30 parts of platycodon grandiflorum, 50 parts of gypsum, 35 parts of radix scutellariae, 35 parts of honeysuckles, 15 parts of borneol and 500 parts of mature vinegar. The raw materials are scientific in composition and reasonable in compatibility and support one another, the medicines are used together, and the external application medicine has the effects of clearing away heat and toxic materials, promoting blood circulation to remove meridian obstruction and relieving pain, is short in treatment time, takes effect quickly, is high in cure rate,free of toxic and side effects and especially suitable for treating herpes zoster, and truly achieves the effects of simplicity, convenience, low cost and effectiveness.

The invention discloses a filtering method adopted in a preparing process of an arenobufagin injection. The filtering method comprises the following specific steps: 10-15 g of arenobufagin is taken and soaked in propylene glycol, the arenobufagin is taken out and then placed into a heating room to be dried, and the arenobufagin is ground after being dried; a mixed solution is placed into a refrigerating chamber to be refrigerated, the mixed solution is taken out and then subjected to first-time filtering and second-time filtering, first-time filter residues and second-time filter residues aremixed together, carbon tetrachloride is added, after stirring and dissolving, filtering is carried out, the carbon tetrachloride is heated and recovered, and a third-time clear solution and third-timefilter residues are obtained; and a first-time clear solution, a second-time clear solution and the third-time clear solution are combined, and an arenobufagin extractive is obtained.

The invention relates to the technical field of pharmaceutical chemistry and in particular discloses a pharmaceutical composition and a extract for reversing tumor multidrug resistance. The pharmaceutical composition for reversing the tumor multidrug resistance is characterized by being prepared from the following components in parts by weight: 30 to 60 parts of arenobufagin, 8 to 20 parts of hellebrigenin, 10 to 25 parts of telocinobufagin, 25 to 50 parts of bufotaline, 20 to 40 parts of cinobufotalin, 25 to 50 parts of bufalin, 30 to 60 parts of cinobufagin and 15 to 30 parts of resibufogenin. Cinobufagin venom toad extract takes the pharmaceutical composition as an effective component. The reverse multiple of the pharmaceutical composition on the tumor drug resistance is 30 to 70 times; the reverse multiple of the extract on the tumor drug resistance is 10 to 20 times.